BioSpace News Archive

BioMidwest

Iterum Therapeutics to Present Data at IDWeek 2021

Iterum Therapeutics plc today announced a data presentation at the Infectious Disease Society of America (IDSA) IDWeek TM 2021, taking place virtually from September 29 – October 3, 2021.

September 28, 2021
·
3 min read
Business

Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases

September 28, 2021
·
4 min read
Genetown

Stealth BioTherapeutics Presents Positive Elamipretide Data in Pediatric Cardiology at International Society for Heart Research North American Section Meeting 2021

Stealth BioTherapeutics Corp announced today the presentation of positive elamipretide data showing improvements in mitochondrial respiration and heart muscle function in tissue from failing human hearts at the International Society for Heart Research North American Section Meeting 2021.

September 28, 2021
·
5 min read
Biotech Beach

Arrowhead Earns $10 Million Phase 1 Milestone Payment

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc.

September 28, 2021
·
3 min read
Drug Development

Oncoinvent Announces Advancement of Radspherin® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients

Oncoinvent Announces Advancement of Radspherin ® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients

September 28, 2021
·
2 min read
Drug Development

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder

Dicerna Pharmaceuticals, Inc today announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna’s investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD).

September 28, 2021
·
9 min read
BioMidwest

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem).

September 28, 2021
·
5 min read
Biotech Bay

Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia

Senti Bio, a leading gene circuit company, announced that it has been awarded a Small Business Innovation Research contract to support further development of SENTI-202 for acute myeloid leukemia towards clinical development.

September 28, 2021
·
3 min read
Drug Development

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration

Applied Genetic Technologies Corporation announced a presentation of the Company’s ongoing clinical trials in achromatopsia and X-linked retinitis pigmentosa at the Fourteenth International Symposium on Retinal Degeneration.

September 28, 2021
·
6 min read
Drug Development

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I-Mab (the “Company”) (Nasdaq: IMAB),today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted the Company’s IND application to initiate a phase 2 trial for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda®) in patients with selected solid tumors in China.

September 28, 2021
·
6 min read